Identifying the Vulnerable Patient with Rupture-Prone Plaque

American Journal of Cardiology

Volumn 101, Issue 12 SUPPL., 2008, Pages

  Weintraub, Howard S ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN; PHOSPHOLIPASE A2;

AGING; ARTERY RUPTURE; ARTERY WALL; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; EPIDEMIC; HEART INFARCTION; HUMAN; IMAGING; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; OBESITY; PRIORITY JOURNAL; STENOSIS; STROKE; UNITED STATES; VULNERABLE POPULATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS;

EID: 51749086370     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.04.013     Document Type: Article

References (31)

1. Rosamond R., Flegal K., Friday G., Furie K., Go A., Greenlund K., Haase N., Ho M., Howard V., and Kissela B. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. National Heart, Lung, and Blood Institute. What is the heart truth?. http://www.nhlbi.nih.gov/health/hearttruth/whatis/ Accessed July 30, 2007
3. Khot U.M., Khot N.B., Bajzer C.T., Sapp S.K., Ohman E.M., Brener S.J., Ellis S.G., Lincoff A.M., and Topol E.J. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290 (2003) 898-904
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421 II-30-II-31
5. Tuczu E.M., Kapadia S.R., Tutar E., Ziada K.M., Hobbs R.E., McCarthy P.M., Young J.B., and Nissen S.E. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103 (2001) 2705-2710
6. Murabito J.M., Evans J.C., Larson M.G., and Levy D. Prognosis after the onset of coronary heart disease: an investigation of differences in outcome between the sexes according to initial coronary disease prevention. Circulation 88 (1993) 2548-2555
7. 2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 152 (2006) 997-1003
8. American Cancer Society. Cancer Facts & Figures 2007 (2007), American Cancer Society, Atlanta 4
9. Naghavi M., Falk E., Hecht H.S., Jamieson M.J., Kaul S., Berman D., Fayad Z., Budoff M.J., Rumberger J., Naqvi T.Z., et al. From vulnerable plaque to vulnerable patient. Part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) task force report. Am J Cardiol 98 suppl (2006) 2H-15H
10. Genest J., McNamara J.R., Ordovas J.M., Jenner J.L., Bilberman S.R., Anderson K.M., Wilson P.W., Salem D.N., and Schaefer E.J. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 19 (1992) 792-802
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
12. Akosah K.O., Schaper A., Cogbill C., and Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform?. J Am Coll Cardiol 41 (2003) 1475-1479
13. Glagov S., Weisenberg E., Zarins C.K., Stankunavicius R., and Kolettis G.J. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316 (1987) 1371-1375
14. Henderson R.A., Pocock S.J., Clayton T.C., Knight R., Fox K.A.A., Julian D.G., and Chamberlain D.A. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 42 (2003) 1161-1170
15. Boden W.E., O'Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J., Knudtson M., Dada M., Casperson P., Harris C.L., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007) 1503-1516
16. 2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 2523-2529
17. 2: potential mechanism of inflammatory burden in atherosclerosis. Circulation 114 (2006) II-24 Abstract 258.
18. 2) in young white adults: the HERITAGE family study. Med Sci Sports Exerc 39 suppl (2007) S312
19. Kuvin J.T., Dave D.M., Sliney K.A., Mooney P., Patel A.R., Kimmelsstiel C.D., and Karas R.H. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 98 (2006) 743-745
20. 2) during prescription omega-3 therapy. Program and abstracts of the Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference (2007) April 19-21, 2007; Chicago, Illinois. Abstract P383.
21. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
22. Yeboah J., Crouse J.R., Hsu F.C., Burke G.L., and Herrington D.M. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 115 (2007) 2390-2397
23. Lerman A. Restenosis: another "dysfunction" of the endothelium. Circulation 111 (2005) 8-10
24. Targonski P.V., Bonetti P.O., Pumper G.M., Higano S.T., Holmes D.R., and Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 107 (2003) 2805-2809
25. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption. Circulation 92 (1995) 657-671
26. Virmani R., Burke A.P., Farb A., and Kolodgie F.D. Pathology of the vulnerable plaque. J Am Coll Cardiol 47 (2006) C13-C18
27. Jang I.-K., Tearney G.J., MacNeill B., Takano M., Moselewski F., Iftima N., Shishkov M., Houser S., Aretz H.T., Halpern E.F., and Bouma B.E. In Vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 111 (2005) 1551-1555
28. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J. Clin Invest 112 (2003) 1785-1788
29. 2 is not increased in association with insulin resistance [abstract]. Arterioscler Thromb Vasc Biol 24 (2004) E-67
30. 2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 7 (2007) 511-517
31. 2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 27 (2007) 1411-1416